Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women

Sponsor
Mansoura University
Study ID
NCT07429734
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Overactive Bladder

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • solifenacin combined with gabapentin — DRUG
    using solifenacin combined with gabapentin for treatment of non-neurogenic overactive bladder in women
  • solifenacin monotherapy — DRUG
    solifenacin monotherapy for treatment of non-neurogenic overactive bladder in women

Study Details

The goal of the study is to compare the efficacy, safety and tolerability of solifenacin plus gabapentin versus solifenacin monotherapy for the treatment of women who are suffering from non-neurogenic ОАВ. The main questions it aims to answer are: Does combination of Solifenacin and Gabapentin affect the total score and sub-scores of OABSS in females with non-neurogenic ОАВ ? What medical problems do participants have when taking combination of Solifenacin and gabapentin ?

Key Dates

First listed
Feb 24, 2026
Start date
Feb 28, 2026
Status verified
Feb 2026
Primary completion
Oct 31, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Solifenacin Combined with Gabapentin
    using solifenacin combined with gabapentin for treatment of non-neurogenic overactive bladder in women
  • Sham Comparator: solifenacin monotherapy
    solifenacin monotherapy for treatment of non-neurogenic overactive bladder in women

Primary Outcome Measure

Change from baseline in the total score and sub-scores of Overactive Bladder Symptom Score at follow-up visits. [ Time Frame: 90 days ]

Central Contacts

Related Studies